NCT02120469View on ClinicalTrials.gov

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

March 20, 2019

Study Completion Date

March 3, 2020

Conditions
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor-negativeStage IV Breast CancerTriple-negative Breast Carcinoma
Interventions
DRUG

everolimus

Given PO

DRUG

eribulin mesylate

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (3)

91010

City of Hope Medical Center, Duarte

91030

South Pasadena Cancer Center, South Pasadena

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02120469 - Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter